📑 The symptom burden of #PBC is substantial‼️ 🚨Fatigue: 51% 🚨Pruritus: 33% 🚨Severe Pruritus: 10% ⚠️Yet only 36% of patients with pruritus received treatment❕ ⭐️PBC care must extend beyond biochemical response❕ #LiverX #OpenAccess journals.lww.com/hepcomm/ful…

New kid on the block: get to know iLivTouch elastography journals.lww.com/hepcomm/ful…

🏀 Next up: Surviving HCC—Curative Treatment, Transplant Benefit and Access @akusnik explores which treatments are associated with longer survival, who benefits most from transplant, and who gets access. Thread 👇 #HepMadness2026

5/5 Does this theme earn a spot in your next round? 🏆 Explore the evidence and submit your bracket by Oct 31: tourneytopia.com/aasld/hepma… @LTxJournal @HepCommJournal @aasldtweets #HepMadness2026

🏀 Next up: Falls, Frailty, and Sarcopenia Sirisha Gaddipati explores how physical frailty, muscle loss, and fall risk affect outcomes in cirrhosis. Can this theme stand strong through the competition? 👇 #HepMadness2026

Co-Editors @ebtapper and Carmen Chak-Lui Wong highlight October's @HepCommJournal, featuring liver decompensation, acute kidney injury in alcohol-associated hepatitis, pediatric PSC, ferroptosis, and more! Watch below and explore the issue: journals.lww.com/hepcomm/toc… piped.video/QniIrUn-Sfo

📑 Seladelpar in patients with #PBC and compensated #cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies‼️ #OpenAccess #LiverX journals.lww.com/hepcomm/ful…

📑#MetALD is emerging as a major 🌎 liver disease phenotype‼️ ⭐️10-20% of people with hepatic steatosis meet MetALD criteria❕ ⚠️Metabolic dysfunction ➕ alcohol 🍻➡️ increased risks of fibrosis progression, cirrhosis, & HCC❕ #OpenAccess journals.lww.com/hepcomm/ful…

Pleased to share our study on gaps in awareness of metabolic liver disease. Among 1,000 US adults with elevated metabolic risk, 60% recognized “fatty liver disease,” but only 13% were familiar with #MASLD and 12% with #MASH. Just 13% reported concern about liver disease. These findings reinforce why liver health needs to be part of our everyday conversations with patients about obesity and diabetes. ovid.com/jnls/hepcomm/fullte…

📑 L-Taurine for #Fatigue in Decompensated Cirrhosis⁉️ ❎ Negative trial overall ⭐️ BUT, patients without anemia🩸 had a large ⬇️ in fatigue 😴, while those with anemia did not❕ #OpenAccess #LiverX journals.lww.com/hepcomm/ful…

📑 Low serum pseudocholinesterase levels are associated with mortality in patients with #HCC‼️ #OpenAccess #LiverX journals.lww.com/hepcomm/ful…

Have you signed up for #HepMadness2026 yet? 🏆 16 hepatology themes go head-to-head! A great learning opportunity with recent articles handpicked from @LTxJournal & @HepCommJournal, summarized by team @LiverFellow. Open to ALL! Make your picks by Oct 31! 🔥 Sign up & FAQs here 🔗 aasld.org/liver-fellow-n… 🥇 to be announced at #TLM2026 @AASLDtweets @AASLDFoundation @AASLDPresident @ebtapper @jlouissaint89 @WAleyadeh @SarahKhan9894

Huge review on patient and caregiver reported outcome in ascites from Dr Sumita Verma’s group journals.lww.com/hepcomm/ful… Open access in @HepCommJournal Everything from pooled estimates to impact of interventions

5/5 Does this theme make your next round—or go all the way? 🏆 Submit your bracket by Oct 31: tourneytopia.com/aasld/hepma… @LTxJournal @HepCommJournal @aasldtweets #HepMadness2026

5/5 Is this your championship pick? 🏆 Explore the evidence and submit your bracket by Oct 31: tourneytopia.com/aasld/hepma… @LTxJournal @HepCommJournal @aasldtweets #HepMadness2026

📑 Group-based #telehealth 💻behavioral interventions for chronic liver disease‼️ A 14-week group telehealth intervention achieved 84% retention & 91% session attendance❕ ⭐️Improvement trends in stress, coping, relaxation 🧘, & sleep hygiene 😴 journals.lww.com/hepcomm/ful…

1/6 🚨 THE BRACKET IS LIVE 🚨 HepMadness 2026 starts NOW. 16 themes. 4 rounds. 1 champion 🏆 The best hepatology and transplant science of the year, going head to head. Who survives? #HepMadness2026 aasld.org/liver-fellow-netwo…

📑 Autoimmune liver diseases in Latin America 🌎: Current landscape and challenges‼️ #OpenAccess #LiverX #PBC #AIH journals.lww.com/hepcomm/ful…

📑 Molnupiravir is effective against hepatitis E virus infection in an animal model‼️🦠 #OpenAccess #LiverX journals.lww.com/hepcomm/ful…

🎉 A historic milestone for AASLD journals! @HEP_Journal has achieved its highest-ever #ImpactFactor of 21.3, reinforcing its position as a global leader in liver research and scientific discovery. The milestones don't stop there! @HepCommJournal also reached a record-high Impact Factor of 6.2. These achievements reflect the exceptional contributions of our authors, reviewers, and editorial teams and AASLD's continued commitment to advancing liver science and improving patient care worldwide. Read the full announcement: bit.ly/4jndxRJ